Sunstone

Plus: Forbion and Ysios Capital’s Kynexis debuts and updates from BioMarin, Flagship, Gilead, Arcus, Takeda and the FTC

Plus: Early stop for Novo’s kidney outcomes study of semaglutide; Agomab raises $100M series B; and updates from MinervaX, FDA, ARPA-H, Tempest, Kanvas-Federation Bio

Plus: Servier’s vorasidenib meets glioma endpoint and updates from Teitur, AlgoTx, GSK, Acesion, Sophia Genetics and more 

Dutch start-up with about €40M in funding will advance fusion protein targeting von Willebrand factor for two indications

Months after launch, Organon signals appetite for more deals

Crinetics spins out radiotherapeutics company, IO Biotech, Calithera, Sana and more

German company’s goal is disease-modification, a sign of lead investor Inkef Capital’s growing ambition in life sciences.  

Early access to the Scandinavian public markets can create problems for finding growth capital

French biotech considering accelerated pathway for lead program

IO Biotech parlayed early clinical data into a €127 million ($154.8 million) series B financing led by HBM Healthcare Investments, which will support a Phase II trial of its leading cancer